Results 141 to 150 of about 59,126 (309)

Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy [PDF]

, 2017
Mara Medeiros-Domingo, L Velásquez-Jones, Ana M Guerreiro Hernández, Guillermo Ramón‐García, Saúl Valverde, Yolanda Fuentes, Arindal Vargas, Mauricio Patiño, Rosalba Pérez‐Villalva, Juan Antonio Ortega-Trejo, Jonatan Barrera‐Chimal, Norma A. Bobadilla   +11 more
openalex   +1 more source

Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper

ESC Heart Failure, EarlyView.
The graphical abstract summarizes the key features of AFMR in terms of epidemiology, pathophysiology, diagnosis, medical therapy and rhythm control, surgical and transcatheter interventions, and future directions. Created in BioRender (https://BioRender.com/3zj03ko).
Matteo Pagnesi, Mauro Riccardi, Francesco Maisano, Julia Grapsa, Vassilis Barberis, Magdy Abdelhamid, Elena‐Laura Antohi, Henrike Arfsten, Nicole Karam, Denisa Muraru, Karl‐Philipp Rommel, Anna Sannino, Wilfried Mullens, Marianna Adamo, Marco Metra   +14 more
wiley   +1 more source

Effects of Mineralocorticoid Receptor Gene Disruption on the Components of the Renin-Angiotensin System in 8-Day-Old Mice [PDF]

, 1999
Christine Hübert, Jean-Marie Gasc, Stefan Berger, Günther Schütz, Pierre Corvol   +4 more
openalex   +1 more source

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

ESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage, Jason N. Dungu, Anthony Dimarco, Brian Li, Samantha Langley, Jonathan Kojo Amoah, Paraic Cliffe, Archana Ganapathy, Peter Watters, Patricia Campbell, Nicola Melarkey, Simon Duckett, Sean Davies, Matthew Dewhurst, Karen Hann, Louise Clayton, Rhys Williams, Victoria Ruszala, Teresa Onwere‐Tan, Fozia Zahir Ahmed, Ibrahim Arosi, Kimberly Gray, Mark C. Petrie, John G.F. Cleland   +23 more
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source

Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial

ESC Heart Failure, EarlyView.
Central Illustration caption: This analysis of vericiguat's treatment effect revealed no inter‐geographic region heterogeneity for the primary composite endpoint (time to HF‐related hospitalization or cardiovascular (CV) death or its components) (Left Panel).
Cynthia M. Westerhout, Wendimagegn Alemayehu, Alain Cohen‐Solal, Carolyn S. P. Lam, Justin A. Ezekowitz, Stefano Corda, Ciaran J. McMullan, Christopher M. O'Connor, Paul W. Armstrong, for the VICTORIA Study Group   +9 more
wiley   +1 more source

Natural and Synthetic Corticosteroids Inhibit Uptake\u3csub\u3e2\u3c/sub\u3e-Mediated Transport in CNS Neurons [PDF]

, 2011
In addition to exerting actions via mineralocorticoid and glucocorticoid receptors, corticosteroids also act by inhibiting uptake2, a high-capacity monoamine transport system originally described in peripheral tissues.
Gasser, Paul J., Hill, Jonathan E., Hillard, Cecilia J., Makky, Khadijah, Shrestha, Lalita   +4 more
core   +1 more source

Percutaneous endocardial alginate–hydrogel injection in the treatment of heart failure: First‐in‐human study

ESC Heart Failure, EarlyView.
Using EndoWings™ and XDROP™, we developed a percutaneous minimally invasive technique for sequential circumferential alginate hydrogel injection into LV free mid‐wall. This human study assessed its safety/feasibility in HFrEF patients, with personalised biomechanical models.
Bo Wang, Shuo Wang, Chao Gao, D. Scott Lim, Rutao Wang, Xin Meng, Ying Liu, Cun‐jun Zhu, Yoshinobu Onuma, Yunbing Wang, Patrick W.J.C. Serruys, Runlin Gao, Randall J. Lee, Ling Tao   +13 more
wiley   +1 more source

Mineralocorticoid receptor antagonists modulate ST2 signaling pathway in chronic heart failure [PDF]

, 2013
M. Lopez, Jesús Sánchez‐Más, Domingo A. Pascual‐Figal, Luis Caballero, María Josefa Fernández del Palacio, Giorgia Santarelli, S. Abenza, María T. Pérez-Martínez, Mariano Valdés‐Chávarri, A. M. Lax   +9 more
openalex   +1 more source